The Polycystic Ovary Morphology-Polycystic Ovary Syndrome Spectrum

Journal of Pediatric and Adolescent Gynecology

Volumn 28, Issue 6, 2015, Pages 412-419

  Rosenfield, Robert L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Glucose intolerance; Insulin resistance; Obesity; Polycystic ovary; Polycystic ovary syndrome

Indexed keywords

ADOLESCENT; ADULT; ANOVULATION; CONTROLLED STUDY; DISEASE CARRIER; DISEASE SEVERITY; FEMALE; GLUCOSE INTOLERANCE; HUMAN; HYPERANDROGENISM; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; OBESITY; OVARY FOLLICLE DEVELOPMENT; OVARY FUNCTION; OVARY POLYCYSTIC DISEASE; PREVALENCE; PRIORITY JOURNAL; SHORT SURVEY; BLOOD; OVARY; PATHOPHYSIOLOGY; PHENOTYPE; POLYCYSTIC OVARY SYNDROME;

HYDROXYPROGESTERONE;

17-ALPHA-HYDROXYPROGESTERONE; ADOLESCENT; ADULT; ANOVULATION; FEMALE; HUMANS; HYPERANDROGENISM; INSULIN RESISTANCE; OVARY; PHENOTYPE; POLYCYSTIC OVARY SYNDROME;

EID: 84946490140     PISSN: 10833188     EISSN: 18734332     Source Type: Journal    
DOI: 10.1016/j.jpag.2014.07.016     Document Type: Short Survey

References (73)

1. Azziz R., Sanchez L.A., Knochenhauer E.S., et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab 2004, 89:453.
2. Carmina E., Rosato F., Janni A., et al. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab 2006, 91:2.
3. Ehrmann D.A., Barnes R.B., Rosenfield R.L. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr Rev 1995, 16:322.
4. Rosenfield R.L. Clinical review: Identifying children at risk of polycystic ovary syndrome. J Clin Endocrinol Metab 2007, 92:787.
5. Franks S. Polycystic ovary syndrome in adolescents. Int J Obes (Lond) 2008, 32:1035.
6. Stein I.F., Leventhal M.L. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935, 29:181.
7. Zawadzki J., Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. Polycystic Ovary Syndrome 1992, 377. Blackwell Scientific Publications, Cambridge, MA. A. Dunaif, J. Givens, F. Haseltine (Eds.).
8. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004, 81:19.
9. Azziz R., Carmina E., Dewailly D., et al. Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess and PCOS Society: The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009, 91:456.
10. Johnson T., Kaplan L., Ouyang P., et al. National Institutes of Health evidence-based methodology workshop on polycystic ovary syndrome (PCOS) 2013, 1. NIH EbMW Report, National Institutes of Health, Bethesda, MD, Accessed November 14, 2014. https://prevention.nih.gov/programs-events/pathways-to-prevention/previous-workshops/pcos/workshop-resources.
11. Adams J.M., Taylor A.E., Crowley W.F., et al. Polycystic ovarian morphology with regular ovulatory cycles: insights into the pathophysiology of polycystic ovarian syndrome. J Clin Endocrinol Metab 2004, 89:4343.
12. Barber T.M., Wass J.A., McCarthy M.I., et al. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome. Clin Endocrinol 2007, 66:513.
13. Guastella E., Longo R.A., Carmina E. Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes. Fertil Steril 2010, 94:2197.
14. Carmina E., Chu M.C., Longo R.A., et al. Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab 2005, 90:2545.
15. Burgers J.A., Fong S.L., Louwers Y.V., et al. Oligoovulatory and anovulatory cycles in women with polycystic ovary syndrome (PCOS): what's the difference?. J Clin Endocrinol Metab 2010, 95:E485.
16. Brower M., Brennan K., Pall M., et al. The severity of menstrual dysfunction as a predictor of insulin resistance in PCOS. J Clin Endocrinol Metab 2013, 98:E1967.
17. Pelusi C., Fanelli F., Pariali M., et al. Parallel variations of insulin-like peptide 3 (INSL3) and antimüllerian hormone (AMH) in women with the polycystic ovary syndrome according to menstrual cycle pattern. J Clin Endocrinol Metab 2013, 98:E1575.
18. Moghetti P., Tosi F., Bonin C., et al. Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome. J Clin Endocrinol Metab 2013, 98:E628.
19. Hosseinpanah F., Barzin M., Keihani S., et al. Metabolic aspects of different phenotypes of polycystic ovary syndrome: Iranian PCOS Prevalence Study. Clin Endocrinol 2014, 81:93.
20. Legro R.S., Arslanian S.A., Ehrmann D.A., et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2013, 98:4565.
21. Rosenfield R.L. Clinical review: Adolescent anovulation: maturational mechanisms and implications. J Clin Endocrinol Metab 2013, 98:3572.
22. Carmina E., Oberfield S.E., Lobo R.A. The diagnosis of polycystic ovary syndrome in adolescents. Am J Obstet Gynecol 2010, 203:201.e1.
23. Rosenfield R.L., Mortensen M., Wroblewski K., et al. Determination of the source of androgen excess in functionally atypical polycystic ovary syndrome by a short dexamethasone androgen-suppression test and a low-dose ACTH test. Hum Reprod 2011, 26:3138.
24. Rosenfield R.L., Wroblewski K., Padmanabhan V., et al. Antimüllerian hormone levels are independently related to ovarian hyperandrogenism and polycystic ovaries. Fertil Steril 2012, 98:242.
25. Mortensen M., Ehrmann D.A., Littlejohn E., et al. Asymptomatic volunteers with a polycystic ovary are a functionally distinct but heterogeneous population. J Clin Endocrinol Metab 2009, 94:1579.
26. Ibañez L., Hall J.E., Potau N., et al. Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing. J Clin Endocrinol Metab 1996, 81:4103.
27. Nelson V.L., Legro R.S., Strauss J.F., et al. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol 1999, 13:946.
28. Jonard S., Dewailly D. The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Hum Reprod Update 2004, 10:107.
29. Littlejohn E.E., Weiss R.E., Deplewski D., et al. Intractable early childhood obesity as the initial sign of insulin resistant hyperinsulinism and precursor of polycystic ovary syndrome. J Pediatr Endocrinol Metab 2007, 20:41.
30. Ibañez L., Lopez-Bermejo A., del Rio L., et al. Combined low-dose pioglitazone, flutamide, and metformin for women with androgen excess. J Clin Endocrinol Metab 2007, 92:1710.
31. Goldzieher M.W., Green J.A. The polycystic ovary. I. Clinical and histologic features. J Clin Endocrinol Metab 1962, 22:325.
32. Hughesdon P.E. Morphology and morphogenesis of the Stein-Leventhal ovary and of so-called "hyperthecosis". Obstet Gynecol Surv 1982, 37:59.
33. Walters K.A., Allan C.M., Handelsman D.J. Androgen actions and the ovary. Biol Reprod 2008, 78:380.
34. Hoffman F., Meger R.C. Geburtshilfe Frauenheilklinic 1965, 25:1132.
35. Hillier S., Ross C. Effects of exogenous testosterone on ovarian weight, follicular morphology and intraovarian progesterone concentration in estrogen-primed hypophysectomized immature female rats. Biol Reprod 1979, 20:261.
36. Futterweit W., Deligdisch L. Histopathological effects of exogenously administered testosterone in 19 female to male transsexuals. J Clin Endocrinol Metab 1986, 62:16.
37. Pache T.D., Chadha S., Gooren L.J., et al. Ovarian morphology in long-term androgen-treated female to male transsexuals. A human model for the study of polycystic ovarian syndrome?. Histopathology 1991, 19:445.
38. Piouka A., Farmakiotis D., Katsikis I., et al. Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am J Physiol Endocrinol Metab 2009, 296:E238.
39. Pigny P., Jonard S., Robert Y., et al. Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab 2006, 91:941.
40. Dewailly D., Gronier H., Poncelet E., et al. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod 2011, 26:3123.
41. Stubbs S.A., Hardy K., Da Silva-Buttkus P., et al. Anti-müllerian hormone protein expression is reduced during the initial stages of follicle development in human polycystic ovaries. J Clin Endocrinol Metab 2005, 90:5536.
42. Franks S., Stark J., Hardy K. Follicle dynamics and anovulation in polycystic ovary syndrome. Hum Reprod Update 2008, 14:367.
43. Zhang T., Liang W., Fang M., et al. Association of the CAG repeat polymorphisms in androgen receptor gene with polycystic ovary syndrome: a systemic review and meta-analysis. Gene 2013, 524:161.
44. Rosenfield R.L., Bordini B. Evidence that obesity and androgens have independent and opposing effects on gonadotropin production from puberty to maturity. Brain Res 2010, 1364:186.
45. Polson D.W., Adams J., Wadsworth J., et al. Polycystic ovaries-a common finding in normal women. Lancet 1988, 331:870.
46. Farquhar C.M., Birdsall M., Manning P., et al. The prevalence of polycystic ovaries on ultrasound scanning in a population of randomly selected women. Aust N Z J Obstet Gynaecol 1994, 34:67.
47. Gilling-Smith C., Story H., Rogers V., et al. Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1997, 47:93.
48. Chang P.L., Lindheim S.R., Lowre C., et al. Normal ovulatory women with polycystic ovaries have hyperandrogenic pituitary-ovarian responses to gonadotropin-releasing hormone-agonist testing. J Clin Endocrinol Metab 2000, 85:995.
49. Legro R.S., Chiu P., Kunselman A.R., et al. Polycystic ovaries are common in women with hyperandrogenic chronic anovulation but do not predict metabolic or reproductive phenotype. J Clin Endocrinol Metab 2005, 90:2571.
50. Johnstone E.B., Rosen M.P., Neril R., et al. The polycystic ovary post-rotterdam: a common, age-dependent finding in ovulatory women without metabolic significance. J Clin Endocrinol Metab 2010, 95:4965.
51. Hart R., Doherty D.A., Norman R.J., et al. Serum antimullerian hormone (AMH) levels are elevated in adolescent girls with polycystic ovaries and the polycystic ovarian syndrome (PCOS). Fertil Steril 2010, 94:1118.
52. Villarroel C., Merino P.M., López P., et al. Polycystic ovarian morphology in adolescents with regular menstrual cycles is associated with elevated anti-Mullerian hormone. Hum Reprod 2011, 26:2861.
53. Freeman E.W., Sammel M.D., Lin H., et al. Anti-mullerian hormone as a predictor of time to menopause in late reproductive age women. J Clin Endocrinol Metab 2012, 97:1673.
54. Murphy M.K., Hall J.E., Adams J.M., et al. Polycystic ovarian morphology in normal women does not predict the development of polycystic ovary syndrome. J Clin Endocrinol Metab 2006, 91:3878.
55. Corbett S., Morin-Papunen L. The Polycystic Ovary Syndrome and recent human evolution. Mol Cell Endocrinol 2013, 373:39.
56. Mortensen M., Rosenfield R.L., Littlejohn E. Functional significance of polycystic-size ovaries in healthy adolescents. J Clin Endocrinol Metab 2006, 91:3786.
57. Codner E., Villarroel C., Eyzaguirre F.C., et al. Polycystic ovarian morphology in postmenarchal adolescents. Fertil Steril 2011, 95:702-6.e1.
58. Balen A.H., Laven J.S., Tan S.L., et al. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update 2003, 9:505.
59. Duijkers I.J., Klipping C. Polycystic ovaries, as defined by the 2003 Rotterdam consensus criteria, are found to be very common in young healthy women. Gynecol Endocrinol 2010, 26:152.
60. Bentzen J.G., Forman J.L., Johannsen T.H., et al. Ovarian antral follicle subclasses and anti-mullerian hormone during normal reproductive aging. J Clin Endocrinol Metab 2013, 98:1602.
61. Dewailly D., Lujan M.E., Carmina E., et al. Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update 2014, 20:334.
62. Alsamarai S., Adams J.M., Murphy M.K., et al. Criteria for polycystic ovarian morphology in polycystic ovary syndrome as a function of age. J Clin Endocrinol Metab 2009, 94:4961.
63. Lujan M.E., Jarrett B.Y., Brooks E.D., et al. Updated ultrasound criteria for polycystic ovary syndrome: reliable thresholds for elevated follicle population and ovarian volume. Hum Reprod 2013, 28:1361.
64. Bridges N.A., Cooke A., Healy M.J., et al. Standards for ovarian volume in childhood and puberty. Fertil Steril 1993, 60:456.
65. Hickey M., Doherty D.A., Atkinson H., et al. Clinical, ultrasound and biochemical features of polycystic ovary syndrome in adolescents: implications for diagnosis. Hum Reprod 2011, 26:1469.
66. Venturoli S., Porcu E., Fabbri R., et al. Longitudinal change of sonographic ovarian aspects and endocrine parameters in irregular cycles of adolescence. Pediatr Res 1995, 38:974.
67. van Hooff M.H., Voorhorst F.J., Kaptein M.B., et al. Polycystic ovaries in adolescents and the relationship with menstrual cycle patterns, luteinizing hormone, androgens, and insulin. Fertil Steril 2000, 74:49.
68. Avvad C.K., Holeuwerger R., Silva V.C., et al. Menstrual irregularity in the first postmenarchal years: an early clinical sign of polycystic ovary syndrome in adolescence. Gynecol Endocrinol 2001, 15:170.
69. Chen Y., Yang D., Li L., et al. The role of ovarian volume as a diagnostic criterion for Chinese adolescents with polycystic ovary syndrome. J Pediatr Adolesc Gynecol 2008, 21:347.
70. Brown M., Park A.S., Shayya R.F., et al. Ovarian imaging by magnetic resonance in adolescent girls with polycystic ovary syndrome and age-matched controls. J Magn Reson Imaging 2013, 38:689.
71. Adams J., Franks S., Polson D.W., et al. Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotrophin releasing hormone. Lancet 1985, 2:1375.
72. Villa P., Rossodivita A., Sagnella F., et al. Ovarian volume and gluco-insulinaemic markers in the diagnosis of PCOS during adolescence. Clin Endocrinol (Oxf) 2013, 78:285.
73. Radivojevic U.D., Lazovic G.B., Kravic-Stevovic T.K., et al. Differences in anthropometric and ultrasonographic parameters between adolescent girls with regular and irregular menstrual cycles: a case-study of 835 cases. J Pediatr Adolesc Gynecol 2014, 27:227.